DOCSLIB.ORG

Temporary Compliance Waiver Notice the Linked Files May Not Be Fully Accessible to Readers Using Assistive Technology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Temporary Compliance Waiver Notice the Linked Files May Not Be Fully Accessible to Readers Using Assistive Technology Temporary Compliance Waiver Notice The linked files may not be fully accessible to readers using assistive technology. We regret any inconvenience that this may cause our readers. In the event you are unable to read the documents or portions thereof, please email [email protected] or call 1-877-287-1373. Philip Morris Products S.A. THS Page 1 PMI Research & Development 2.7 Executive Summary MRTPA Section 2.7 Executive Summary Confidentiality Statement Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International. Philip Morris Products S.A. THS Page 2 PMI Research & Development 2.7 Executive Summary TABLE OF CONTENTS 2.7.1 EXECUTIVE SUMMARY .....................................................................................9 2.7.2 PROPOSED MODIFIED RISK AND MODIFIED EXPOSURE CLAIMS ........15 2.7.3 MODIFIED RISK TOBACCO PRODUCTS AND HARM REDUCTION .........17 2.7.4 PRODUCT DESCRIPTION AND SCIENTIFIC RATIONALE ..........................19 Development Rationale and Product Description for THS ............................................19 Heating Instead of Burning Reduces Harmful Constituents ......................................19 Product Description ...................................................................................................20 Scientific Rationale and Assessment Framework for THS........................................24 Causal Linkages between HPHC Exposure and Disease ...........................................24 Smoking Cessation – the Gold Standard for Assessing Risk Reduction ...................25 2.7.5 PMI SCIENTIFIC PROGRAM FOR THE ASSESSMENT OF THS ..................28 2.7.6 THE SCIENTIFIC BASIS FOR APPROVAL ......................................................31 A Reduction in Harm and the Risk of Tobacco-Related Disease to Individual Tobacco Users ................................................................................................................31 Product Design and Control Principles (Step 1) ........................................................31 Aerosol Chemistry and Physics (Step 2) ...................................................................34 Standard Toxicology Assessment (Step 3) ................................................................45 Systems Toxicology Assessment (Step 4) .................................................................58 Overall Summary of Non-Clinical Assessment (Steps 3 and 4) ................................72 Clinical Studies (Step 5) ............................................................................................73 Overall Summary of Clinical Studies (Steps 5) .........................................................97 Conclusion Part A: Reduction in Individual Harm and Risk of Tobacco-Related Disease ....................................................................................................................110 B Benefit the Health of the Population as a Whole ..............................................112 Perception and Behavior Assessment (PBA) Framework (Step 6) .........................113 Population Health Impact Model (PHIM) ...............................................................174 Post-market studies and surveillance (Step 7) .........................................................182 Conclusion Part B: Benefit the Health of the Population as a Whole .....................187 2.7.7 OVERALL CONCLUSION ................................................................................190 2.7.8 REFERENCES ....................................................................................................194 Confidentiality Statement Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International. Philip Morris Products S.A. THS Page 3 PMI Research & Development 2.7 Executive Summary LIST OF TABLES Table 1: PMI scientific program for the assessment of THS ............................................ 30 Table 2: PMI-58 list of analytes (excluding product-specific analytes) ........................... 36 Table 3: In vitro assessment of THS aerosol .................................................................... 47 Table 4: Sub-chronic 90-day inhalation studies - selected endpoints and results ........... 52 Table 5: THS clinical assessment ..................................................................................... 74 Table 6: Overview of the measured HPHCs and BoExp .................................................. 77 Table 7: Summary of 5-Day Reduced Exposure Study Results: BoExp [100-(THS:CC) ratio and 100-(SA:CC) ratio in %] in studies ZRHR-REXC-03-EU and ZRHR-REXC-04- JP at Day 5 ........................................................................................................................ 80 Table 8: Summary of 90-Day Reduced Exposure Studies: Reduction of the Primary BoExp at Day 5 and Day 90 [100-(THS:CC) ratio and 100-(SA:CC) ratio in %] ........... 82 Table 9: Adjusted Geometric Least Square Means of THS to CC ratios of the Primary BoExp, NNN and total NNK at Day 5 in two studies conducted in Japan. ...................... 88 Table 10: 8-epi-PGF2α Measured at the Day 90 Visit in the Reduced Exposure - Ambulatory Studies .......................................................................................................... 91 Table 11: 11-DTX-B2 Measured at the Day 90 Visit in the Reduced Exposure - Ambulatory Studies .......................................................................................................... 92 Table 12: FEV1 Measured at the Day 90 Visit in the Reduced Exposure - Ambulatory Studies ............................................................................................................................... 94 Table 13: HDL-Cholesterol Measured at the Day 90 Visit in the Reduced Exposure - Ambulatory Studies .......................................................................................................... 95 Table 14: WBC Counts at the Day 90 Visit in the Reduced Exposure - Ambulatory Studies ............................................................................................................................... 96 Table 15: sICAM-1 Measured at the Day 90 Visit in the Reduced Exposure - Ambulatory Studies ............................................................................................................................... 97 Table 16: PBA Program Structure and WOT Studies .................................................... 116 Table 17: Assessment of consumer responses to product messages............................... 121 Table 18: Modified risk claim and messages for Claim #1 ............................................ 123 Table 19: Modified risk claim and messages for Claim #2 ............................................ 124 Table 20: Modified risk claim and messages for Claim #3 ............................................ 124 Table 21: THS Communication Materials, Warning Type and Study Arms in THS-PBA- 05-US Studies ................................................................................................................. 126 Table 22: Overview of studies conducted on product use .............................................. 131 Confidentiality Statement Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International. Philip Morris Products S.A. THS Page 4 PMI Research & Development 2.7 Executive Summary Table 23: Proportion of Subjects with Positive Intention to Try and Intention to Use THS- Adult Smokers with No Intention to Quit in THS-PBA-03-US ..................................... 133 Table 24: Proportion of Adult Smokers with No Intention to Quit CC with Positive Intention to Try THS and Positive Intention to Use THS in THS-PBA-05 Studies ....... 134 Table 25: Proportion of Subjects with Positive Intention to Try and Intention to Use THS Adult Smokers With the Intention to Quit Smoking in THS-PBA-03-US ..................... 135 Table 26: Proportion of Adult Smokers With the Intention to Quit Smoking with Positive Intention to Try THS and Positive Intention to Use THS in THS-PBA-05-US Studies 136 Table 27: Proportion of Adult Smokers with Intention to Quit Smoking Who Stated a Change in Intention to Quit Smoking or All Tobacco in THS-PBA-05-US Studies...... 139 Table 28: THS Product Messages and Intent to Use in Study THS-PBA-02-US .......... 162 Table 29: Proportion of Adult Nonsmokers with Positive Intention to Try and Positive Intention to Use THS in THS-PBA-05-RRC-US, THS-PBA-05-RRC2-US and THS- PBA-05-REC-US
Load more

Recommended publications
  • I UNITED STATES DISTRICT COURT for the DISTRICT OF
    Case 1:99-cv-02496-PLF Document 6276 Filed 08/03/18 Page 1 of 59 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ____________________________________ UNITED STATES OF AMERICA, ) Plaintiff, ) Civil Action No. 99-CV-2496 (PLF) ) and ) ) CAMPAIGN FOR TOBACCO-FREE ) KIDS, et al., ) Plaintiff-Intervenors, ) ) v. ) ) PHILIP MORRIS USA INC., et al., ) Defendants. ) ) and ) ) ITG BRANDS, LLC, et al., ) Post-Judgment Parties ) Regarding Remedies ) PLAINTIFFS’ 2018 SUPPLEMENTAL BRIEF ON RETAIL POINT OF SALE REMEDY TABLE OF CONTENTS TABLE OF AUTHORITIES ......................................................................................................... iv INTRODUCTION .......................................................................................................................... 1 FACTUAL BACKGROUND ......................................................................................................... 5 I. The Deal between Cigarette Manufacturers and Retailers ............................................... 5 II. Benefits to Participating Retailers .................................................................................... 6 III. Manufacturers’ Contractual Control over Space for Cigarette Marketing and Promotional Displays ....................................................................................................... 8 A. The types of retail advertising and marketing space ........................................8 B. The manufacturers’ contractual authority over participating retailers’ space 10 1. The
    [Show full text]
  • PM 12.31.2014 Form 10K Wrap (Incl F/S & MD&A)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33708 PHILIP MORRIS INTERNATIONAL INC. (Exact name of registrant as specified in its charter) Virginia 13-3435103 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 120 Park Avenue, New York, New York 10017 (Address of principal executive offices) (Zip Code) 917-663-2000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, no par value New York Stock Exchange Floating Rate Notes due 2015 New York Stock Exchange 5.875% Notes due 2015 New York Stock Exchange 2.500% Notes due 2016 New York Stock Exchange 1.625% Notes due 2017 New York Stock Exchange 1.125% Notes due 2017 New York Stock Exchange 1.250% Notes due 2017 New York Stock Exchange 5.650% Notes due 2018 New York Stock Exchange 1.875% Notes due 2019 New York Stock Exchange 2.125% Notes due 2019 New York Stock Exchange 1.750% Notes due 2020 New York Stock Exchange 4.500% Notes due 2020 New York Stock Exchange 1.875% Notes due 2021 New York Stock Exchange 4.125% Notes due 2021 New York Stock Exchange 2.900% Notes due 2021 New York Stock Exchange
    [Show full text]
  • Subject: ACCEPTED FORM TYPE 10-K (0001193125-12-076983) Date: 24-Feb-2012 09:29
    Subject: ACCEPTED FORM TYPE 10-K (0001193125-12-076983) Date: 24-Feb-2012 09:29 THE FOLLOWING SUBMISSION HAS BEEN ACCEPTED BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. COMPANY: Philip Morris International Inc. FORM TYPE: 10-K NUMBER OF DOCUMENTS: 17 RECEIVED DATE: 24-Feb-2012 09:28 ACCEPTED DATE: 24-Feb-2012 09:29 FILING DATE: 24-Feb-2012 09:28 TEST FILING: NO CONFIRMING COPY: NO ACCESSION NUMBER: 0001193125-12-076983 FILE NUMBER(S): 1. 001-33708 THE PASSWORD FOR LOGIN CIK 0001193125 WILL EXPIRE 09-Feb-2013 13:14. PLEASE REFER TO THE ACCESSION NUMBER LISTED ABOVE FOR FUTURE INQUIRIES. REGISTRANT(S): 1. CIK: 0001413329 COMPANY: Philip Morris International Inc. ACCELERATED FILER STATUS: LARGE ACCELERATED FILER FORM TYPE: 10-K FILE NUMBER(S): 1. 001-33708 24-Feb-2012 09:29 Page 1 of 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33708 PHILIP MORRIS INTERNATIONAL INC. (Exact name of registrant as specified in its charter) Virginia 13-3435103 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 120 Park Avenue, New York, New York 10017 (Address of principal executive offices) (Zip Code) 917-663-2000 (Registrant’s telephone number, including area code) Securities registered
    [Show full text]
  • Transforming Our Business
    Transforming our business A cigarette manufacturing line (on the left-hand side) and a heated tobacco unit manufacturing line (on the right-hand side) at our factory in Neuchâtel, Switzerland Replacing cigarettes with While several attempts have been made to develop better alternatives to smoking, smoke-free products drawbacks in the technological capability of these products and a lack of consumer In 2017, PMI manufactured and shipped acceptance rendered them unsuccessful. 791 billion cigarettes and other Recent advances in science and combustible tobacco products and technology have made it possible to 36 billion smoke‑free products, reaching develop innovative products that approximately 150 million adult consumers consumers accept and that are less in more than 180 countries. harmful alternatives to continued smoking. Smoking cigarettes causes serious PMI has developed a portfolio of disease. Smokers are far more likely smoke‑free products, including heated Contribution of Smoke-Free than non‑smokers to get heart disease, tobacco products and nicotine‑containing Products to PMI’s Total lung cancer, emphysema, and other e‑vapor products that have the potential diseases. Smoking is addictive, and it Net Revenues to significantly reduce individual risk and 13% can be very difficult to stop. population harm compared to cigarettes. The best way to avoid the harms of Many stakeholders have asked us about smoking is never to start, or to quit. the role of these innovative smoke‑free But much more can be done to improve products in the context of our business the health and quality of life of those vision. Are these products an extension of who continue to use nicotine products, our cigarette product portfolio? Are they through science and innovation.
    [Show full text]
  • Appendix 1. Categorization of Cigarette Brands As Either Premium Or Discount
    Appendix 1. Categorization of Cigarette Brands as either Premium or Discount Category Name of Cigarette Brand Premium Accord, American Spirit, Barclay, Belair, Benson & Hedges, Camel, Capri, Carlton, Chesterfield, Davidoff, Du Maurier, Dunhill, Dunhill International, Eve, Kent, Kool, L&M, Lark, Lucky Strike, Marlboro, Max, Merit, Mild Seven, More, Nat Sherman, Newport, Now, Parliament, Players, Quest, Rothman’s, Salem, Sampoerna, Saratoga, Tareyton, True, Vantage, Virginia Slims, Winston, Raleigh, Business Club Full Flavor, Ronhill, Dreams Discount 24/7, 305, 1839, A1, Ace, Allstar, Allway Save, Alpine, American, American Diamond, American Hero, American Liberty, Arrow, Austin, Axis, Baileys, Bargain Buy, Baron, Basic, Beacon, Berkeley, Best Value, Black Hawk, Bonus Value, Boston, Bracar, Brand X, Brave, Brentwood, Bridgeport, Bronco, Bronson, Bucks, Buffalo, BV, Calon, Cambridge, Campton, Cannon, Cardinal, Carnival, Cavalier, Champion, Charter, Checkers, Cherokee, Cheyenne, Cimarron, Circle Z, Class A, Classic, Cobra, Complete, Corona, Courier, CT, Decade, Desert Gold, Desert Sun, Discount, Doral, Double Diamond, DTC, Durant, Eagle, Echo, Edgefield, Epic, Esquire, Euro, Exact, Exeter, First Choice, First Class, Focus, Fortuna, Galaxy Pro, Gauloises, Generals, Generic/Private Label, Geronimo, Gold Coast, Gold Crest, Golden Bay, Golden, Golden Beach, Golden Palace, GP, GPC, Grand, Grand Prix, G Smoke, GT Ones, Hava Club, HB, Heron, Highway, Hi-Val, Jacks, Jade, Kentucky Best, King Mountain, Kingsley, Kingston, Kingsport, Knife, Knights,
    [Show full text]
  • Sensational F1 Continues
    Sensational F1 Continues Sponsorship Perspectives September 2009 Simon Lincoln, sponsorship expert at Ipsos MORI, talks about the impact and the trends in brand associations with Formula One. Formula One is never far away from What is the impact of this? the headlines these days: so it seems appropriate to share Ipsos ASI’s thoughts Interest in the sport reached an all-time high in October / November 2008 as Lewis Hamilton and data at this difficult time for the sport. became the sport’s youngest World Champion and as Honda sensationally pulled out the sport. At the Sensational F1! time, this level of interest compared favourably with the nation’s obsession – football. Whilst interest Brawn GP and Jenson Button sensationally domi- in the sport fell back during the close season, the nated the first seven Grand Prix of 2009, winning “Brawn GP factor” kicked in and interest quickly rose six. McLaren had a disastrous start the season with – peaking during the British Grand Prix in late June. an uncompetitive car and some poor management With the current on-and off-the-track headlines, I decision-making at the first Grand Prix in Australia. see no reason why interest should not reach similar Red Bull appeared to have the fastest car but levels in future months. repeatedly failed to make it count when it mattered. Oh, and there were a few off-circuit disputes about Ipsos ASI’s interest in Formula One measure asks the future of the sport and Renault’s admission that people how they follow the sport (watching on TV, three of their former employees conspired to influ- reading in the news / online, listening on the radio ence the outcome a race.
    [Show full text]
  • Altria Group, Inc. Annual Report
    Altria Group, Inc. 2019 Annual Report an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company Howard A. Willard III Dear Fellow Shareholders Chairman of the Board and CEO Altria delivered solid performance in a dynamic year for the tobacco industry. Our core tobacco businesses delivered outstanding financial performance, and we made significant progress advancing our non-combustible product platform. We believe Altria’s enhanced business platform positions us well for future success. 2019 Highlights n Grew adjusted diluted earnings per share (EPS) by 5.8%, primarily driven by our core tobacco businesses; and types of legal cases pending against it, especially during the fourth n Achieved $600 million in annualized cost savings, exceeding our $575 quarter of the year. Altria recorded two impairment charges of our JUUL million target announced in December 2018; asset in 2019, reducing our investment to $4.2 billion at year-end, down from n Increased our regular quarterly dividend for the 54th time in 50 years $12.8 billion, our 2019 initial investment. JUUL remains the U.S. leader in the and paid shareholders approximately $6.1 billion in dividends; and e-vapor category, and in January 2020 we revised certain terms governing n Repurchased 16.5 million Altria shares for a total cost of $845 million.
    [Show full text]
  • Altria Group, Inc. Annual Report
    ananan Altria Altria Altria Company Company Company an Altria Company ananan Altria Altria Altria Company Company Company | Inc. Altria Group, Report 2020 Annual an Altria Company From tobacco company To tobacco harm reduction company ananan Altria Altria Altria Company Company Company an Altria Company ananan Altria Altria Altria Company Company Company an Altria Company Altria Group, Inc. Altria Group, Inc. | 6601 W. Broad Street | Richmond, VA 23230-1723 | altria.com 2020 Annual Report Altria 2020 Annual Report | Andra Design Studio | Tuesday, February 2, 2021 9:00am Altria 2020 Annual Report | Andra Design Studio | Tuesday, February 2, 2021 9:00am Dear Fellow Shareholders March 11, 2021 Altria delivered outstanding results in 2020 and made steady progress toward our 10-Year Vision (Vision) despite the many challenges we faced. Our tobacco businesses were resilient and our employees rose to the challenge together to navigate the COVID-19 pandemic, political and social unrest, and an uncertain economic outlook. Altria’s full-year adjusted diluted earnings per share (EPS) grew 3.6% driven primarily by strong performance of our tobacco businesses, and we increased our dividend for the 55th time in 51 years. Moving Beyond Smoking: Progress Toward Our 10-Year Vision Building on our long history of industry leadership, our Vision is to responsibly lead the transition of adult smokers to a non-combustible future. Altria is Moving Beyond Smoking and leading the way by taking actions to transition millions to potentially less harmful choices — a substantial opportunity for adult tobacco consumers 21+, Altria’s businesses, and society. To achieve our Vision, we are building a deep understanding of evolving adult tobacco consumer preferences, expanding awareness and availability of our non-combustible portfolio, and, when authorized by FDA, educating adult smokers about the benefits of switching to alternative products.
    [Show full text]
  • Heated Tobacco Products' Reduced Exposure Claims
    Research paper Tob Control: first published as 10.1136/tobaccocontrol-2018-054324 on 12 September 2018. Downloaded from Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims Lucy Popova,1 Lauren Kass Lempert,2 Stanton A Glantz2,3 ► Additional material is ABStract As of February 2018, the new HTPs, like PMI’s published online only. To view Introduction Heated tobacco products (HTPs) are IQOS, were being sold in multiple countries around please visit the journal online being marketed in several countries around the world the world in minimalist high-tech looking stores (http:// dx. doi. org/ 10. 1136/ 5–7 tobaccocontrol- 2018- 054324). with claims that they are less harmful than combusted that resemble Apple stores. Advertisements and cigarettes, based on assertions that they expose users marketing materials for IQOS emphasise both its 1School of Public Health, to lower levels of toxicants. In the USA, Philip Morris superiority over combustible cigarettes (in terms Georgia State University, International (PMI) has submitted an application to the of cleanliness and customisability) and similarity Atlanta, Georgia, USA 2Center for Tobacco Control Food and Drug Administration (FDA) in 2016 seeking to them (in terms of product’s taste, size and 6 Research & Education, authorisation to market its HTPs, IQOS, with reduced risk providing similar behavioural experience). Claims University of California, San and reduced exposure claims. about health benefits or lower risks of IQOS are not Francisco, California, USA Methods We examined the PMI’s Perception and emphasised in the marketing materials and some of 3Department of Medicine, Cardiovascular Research Behavior Assessment Studies evaluating perceptions of the materials carry minimal health warnings, such Institute, Philip R.
    [Show full text]
  • PMI Powerpoint Presentation
    Investor Day – Asia Region Lausanne, June 23, 2010 Matteo Pellegrini President, Asia Region Philip Morris International Agenda ● Operating environment ● PMI strategic priorities in Asia ● Brand portfolio and innovations ● Key Asia markets: highlights ● Questions & Answers 2 Operating Environment 2009 • Population : 3.8 billion Korea Japan • Cigarette Volume: 3.4 trillion China Taiwan Cigarette Volume: Pakistan Hong Kong 1.2 trillion units (Excl. – China) Others 15% India Bangladesh Indonesia Thailand Philippines 22% Vietnam Bangladesh 6% Malaysia Pakistan Singapore 6% Vietnam Indonesia 7% Japan 20% Australia Philippines New Zealand 7% Korea 8% India Asia accounts for 56% of the world’s population 9% And 60% of the world’s cigarette volume… Note: Cigarette volumes reflect 2009 Source: Global Insights 3 GDP Per Capita in 15 Key Markets ($ 000) 50 43.9 39.9 36.4 30.4 USA US $ 46,300 European Union US $ 33,100 Asia Pacific US $ 4,000 17.2 16.5 7.0 Asia: $ 4.0 3.9 3.5 2.3 1.8 1.1 1.0 0.9 0.6 0 India China Japan Taiwan Vietnam Thailand Pakistan Malaysia Australia Indonesia Singapore Philippines Hong Kong Bangladesh South Korea Source: Global Insights 4 GDP Growth and Unemployment Rates (%) Japan (%) Australia 7 7 7 7 5.1 4.7 4.1 5.6 3.8 4.0 5.2 4.8 4.4 2.0 2.3 2.0 4.2 2008 2009 4.7 3.3 0 0 2.6 2006 2007 2010 F 2.4 (1.2) 1.3 (5.2) (7) (7) 0 0 GDP Growth Rate 2006 2007 2008 2009 2010 F Unemployment Rate (%) Indonesia (%) Philippines 12 12 12 12 10.3 9.1 8.4 7.9 8.1 8.0 7.3 7.4 7.5 7.3 6.3 6.1 5.5 5.6 5.3 7.1 4.5 3.8 4.2 0.9 0 0 0 0 2006 2007 2008
    [Show full text]
  • Unmanufactured Tobacco, Burley
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Voluntary Report - public distribution Date: 11/30/2000 GAIN Report #PO0032 Portugal Tobacco and Products Annual 2000 Approved by: Robert Wicks U.S. Embassy, Madrid Prepared by: Leonor Ramos Report Highlights: Portuguese 2000 tobacco output is to remain at 6,193 Mt, farm weight basis, and in 2001 at forecast 6,111 Mt. A boosted industrial activity is to lead to an expansion of 2000 total un-manufactured tobacco imports up to estimated 15,000 Mt, and of 2001 imports up to forecast 17,000 Mt. Tobacco imports from the U.S. are to reach estimated 7,500 Mt in 2000, and forecast 8,100 Mt in 2001. 1 USD = 236 Pte. Includes PSD changes: Yes Includes Trade Matrix: Yes Unscheduled Report Madrid [SP1], PO GAIN Report #PO0032 TABLE OF CONTENTS Executive Summary .....................................................1 Commodity Name: Unmanufactured Tobacco, Total ..................................2 Production, Supply & Distribution Table .....................................2 Production ............................................................2 Consumption ..........................................................3 Trade .................................................................4 Policy ................................................................7 Production Quotas .................................................7 Prices and Subsidies ................................................8 Marketing .............................................................9
    [Show full text]
  • Complete Annual Report
    Philip Morris International 2016 Annual Report THIS CHANGES EVERYTHING 2016 Philip Morris Annual Report_LCC/ANC Review Copy February 22 - Layout 2 We’ve built the world’s most successful cigarette company with the world’s most popular and iconic brands. Now we’ve made a dramatic decision. We’ve started building PMI’s future on breakthrough smoke-free products that are a much better choice than cigarette smoking. We’re investing to make these products the Philip Morris icons of the future. In these changing times, we’ve set a new course for the company. We’re going to lead a full-scale effort to ensure that smoke- free products replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. Reduced-Risk Products - Our Product Platforms Heated Tobacco Products Products Without Tobacco Platform Platform 1 3 IQOS, using the consumables Platform 3 is based on HeatSticks or HEETS, acquired technology that features an electronic holder uses a chemical process to that heats tobacco rather Platform create a nicotine-containing than burning it, thereby 2 vapor. We are exploring two Platform creating a nicotine-containing routes for this platform: one 4 vapor with significantly fewer TEEPS uses a pressed with electronics and one harmful toxicants compared to carbon heat source that, once without. A city launch of the Products under this platform cigarette smoke. ignited, heats the tobacco product is planned in 2017. are e-vapor products – without burning it, to generate battery-powered devices a nicotine-containing vapor that produce an aerosol by with a reduction in harmful vaporizing a nicotine solution.
    [Show full text]